aTyr Pharma, Inc. (ATYR)
ATYR moved a median of +0.40% 30 minutes after news, and -0.65% by the close. How ATYR actually reacts to news — the realized, point-in-time move the market made, measured across 884 labeled events over the last three years with zero look-ahead.
ATYR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.26% | 58% | 881 |
| 30-min | +0.40% | 58% | 883 |
| 60-min | +0.01% | 51% | 883 |
| to close | -0.65% | 46% | 861 |
| Middle 50% of ATYR reactions | -1.07% to +2.11% |
|---|---|
| Median reaction (30-min) | +0.40% |
| Measured reactions | 884 |
Half of all aTyr Pharma, Inc. news events land between -1.07% and +2.11% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ATYR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 17 | -0.45% | 35% | -4.21% |
| Coverage initiations | 13 | +2.79% | 77% | -1.58% |
| Rating reiterations | 28 | +0.34% | 68% | -0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ATYR ranks against every other measured name →
That’s how ATYR usually reacts — get an email when it moves on news →Email me when ATYR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATYR's baseline. Nothing else.
Recent ATYR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K aTYR PHARMA INC For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry | Press release | GlobeNewswire | -2.32% | -8.59% | |
| aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis | Press release | GlobeNewswire | -8.20% | -17.11% | |
| Form 8-K aTYR PHARMA INC For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -8.20% | -17.11% | |
| Form DEF 14A aTYR PHARMA INC For: Oct 16 | SEC filing · Form DEF | SEC EDGAR | +2.38% | -7.48% | |
| aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis | Press release | GlobeNewswire | +2.41% | +2.26% | |
| Form PRE 14A aTYR PHARMA INC For: Oct 16 | SEC filing · Form PRE | SEC EDGAR | -3.70% | -1.54% | |
| aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD | Press release | GlobeNewswire | +0.31% | — | |
| Form 10-Q aTYR PHARMA INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.31% | — | |
| Form 8-K aTYR PHARMA INC For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | — | |
| Form S-8 aTYR PHARMA INC | SEC filing · Form S-8 | SEC EDGAR | +0.31% | — | |
| Form 8-K aTYR PHARMA INC For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -0.16% | |
| aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 | Press release | GlobeNewswire | -1.76% | +2.06% | |
| Form 8-K aTYR PHARMA INC For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.90% | +0.13% | |
| Form 8-K aTYR PHARMA INC For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -3.02% | -7.14% | |
| aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | Press release | GlobeNewswire | -9.02% | -13.10% | |
| Form 10-Q aTYR PHARMA INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.40% | +2.65% | |
| Form 8-K aTYR PHARMA INC For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -9.02% | -13.10% | |
| aTyr Pharma to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +18.97% | +34.30% | |
| aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting | Press release | GlobeNewswire | -5.88% | -33.73% | |
| Form 8-K aTYR PHARMA INC For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -5.88% | -33.73% | |
| Form ARS aTYR PHARMA INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.19% | -3.07% | |
| Form DEF 14A aTYR PHARMA INC For: Mar 26 | SEC filing · Form DEF | SEC EDGAR | -0.19% | -3.07% | |
| Form DEFA14A aTYR PHARMA INC | SEC filing · Form DEFA14A | SEC EDGAR | -0.19% | -3.07% | |
| Form PRE 14A aTYR PHARMA INC For: Mar 12 | SEC filing · Form PRE | SEC EDGAR | +1.50% | -3.41% | |
| aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update | Press release | GlobeNewswire | -0.65% | -5.79% | |
| Form 10-K aTYR PHARMA INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.65% | -5.79% | |
| Form 8-K aTYR PHARMA INC For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | -5.79% | |
| aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.72% | -3.81% | |
| aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | -0.65% | +2.36% | |
| aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis | Press release | GlobeNewswire | +4.39% | -1.73% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | -0.24% | -0.65% | |
| Form 8-K aTYR PHARMA INC For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +2.50% | +1.52% | |
| SueWallSt Podcast Series Launches With Focus on aTyr Pharma, Inc. (ATYR) Fraud Allegations | Press release | ACCESS Newswire | -0.24% | -0.65% | |
| Latest SueWallSt Podcast: What ATYR Investors Need to Know About the Lawsuit | Press release | ACCESS Newswire | +1.80% | +9.33% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | -0.57% | -4.68% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +0.38% | +0.52% | |
| aTyr Pharma, Inc. (ATYR) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | -1.30% | +0.97% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +1.14% | +1.99% | |
| Latest SueWallSt Podcast: What ATYR Investors Need to Know About the Lawsuit | Press release | ACCESS Newswire | +6.04% | +17.82% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +3.16% | +3.38% | |
| Latest SueWallSt Podcast: What ATYR Investors Need to Know About the Lawsuit | Press release | ACCESS Newswire | +3.16% | +3.38% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +2.83% | +2.70% | |
| aTyr Pharma, Inc. (ATYR) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | +0.56% | +9.00% | |
| Tune Into the SueWallSt Podcast: aTyr Pharma, Inc. (ATYR) Lawsuit Explained | Press release | ACCESS Newswire | +3.25% | -6.08% | |
| aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +2.62% | -2.47% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +2.62% | -2.47% | |
| aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update | Press release | GlobeNewswire | +2.03% | +8.92% | |
| aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR | Press release | GlobeNewswire | +0.56% | -4.90% | |
| Form 10-Q aTYR PHARMA INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.03% | +8.92% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATYR section they belong to.
Where else ATYR is measured.
ATYR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is aTyr Pharma, Inc.'s median reaction calculated?
Every labeled ATYR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 884 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of ATYR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATYR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.